BNP Paribas Asset Management
BEAM icon

BNP Paribas Asset Management’s Beam Therapeutics BEAM Stock Holding History

BNP Paribas Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.1K Sell
1,227
-297
-19% -$8.97K ﹤0.01% 1818
2026
Q1 		$36.3K Buy
1,524
+372
+32% +$10.3K ﹤0.01% 1849
2025
Q4 		$32K Buy
1,152
+408
+55% +$10.4K ﹤0.01% 1799
2025
Q3 		$18K Hold
744
– – ﹤0.01% 1422
2025
Q2 		$13K Buy
+744
New +$13K ﹤0.01% 1662

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BNP Paribas Asset Management's BEAM Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Beam Therapeutics (BEAM) stake by 19% in Q2 2026, selling an estimated $8.97K and leaving 1,227 shares worth $42.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1818.

BNP Paribas Asset Management first reported a position in BEAM in Q2 2025 and has held it in 5 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • BNP Paribas Asset Management held 1,227 shares of Beam Therapeutics worth $42.1K as of Q2 2026.
  • BNP Paribas Asset Management sold 297 Beam Therapeutics shares in Q2 2026, an estimated $8.97K.
  • Beam Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1818 holding.
  • BNP Paribas Asset Management first reported a position in Beam Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.